AETNA BETTER HEALTH OF TEXAS Provider Relations newsletter

Size: px
Start display at page:

Download "AETNA BETTER HEALTH OF TEXAS Provider Relations newsletter"

Transcription

1 AETNA BETTER HEALTH OF TEXAS Provider Relations newsletter Summer 2017 Table of contents Chief Medical Officer Comments and New Guideline Application...1 Chief Medical Officer Comments and Pharmacy Corner...2 Allergic Rhinitis...3 Improving Continuity of Care for Children with ADHD...4 Promoting Good Outcomes for Depression Management...5 Utilization Management...5 Who to call? TX Chief Medical Officer Comments and New Guideline Application Jim Small, MD, MPH, MMM, FACPM I would like to thank all of our physicians and providers for your concern and conscientious delivery of quality care to your patients and our members of Aetna Better Health Texas. We know it is not easy to provide care, manage or participate in necessary business activities, and successfully negotiate all of the external administrative demands from payers and government agencies. We at Aetna want to work with you in providing quality care. We exist not only to reimburse you for appropriate services you deliver, but to work with you and the State to promote better health for the Star and CHIP populations. To that end we incentivize providers for quality (as measured by certain HEDIS metrics) and we work to ensure benefits are provided at an appropriate level of care and place of service. One of the processes we use to help ensure that the appropriate level of care and place of service is occurring is utilization review where requests are reviewed against established guidelines. At times, we realize this can cause some friction between the requesting provider and us. Approximately two years ago we delegated OB ultrasound reviews to evicore, formerly known as Med Solutions. With some members receiving a high number of OB ultrasounds per gestation, upwards 50 OB ultrasounds per gestation, we thought it prudent to have evicore apply established and periodically evaluated guidelines to OB ultrasound requests. Basically the first four OB ultrasounds are auto approved with notification to evicore. Subsequent ultrasounds require a prior authorization by evicore. More specifically, for a woman presenting during the 1st trimester CPT codes 76801, 76805, 76813, and are auto approved with notification. For a woman presenting in the 2nd or 3rd trimester CPT codes and will be auto approved with notification. Batch requests may receive Continued on page 2 1

2 Chief Medical Officer Comments and New Guideline Application Continued from page 1 a prior authorization for high risk pregnancies. Effective September 5, 2017 we will also be delegating the review of approximately 56 outpatient cardiac imaging requests for Star (not STAR Kids) and CHIP to evicore. Requests will be taken as of August 22 for outpatient cardiac procedures to be scheduled on or after September 5. Additionally, there will some training sessions offered in August to explain the process of requesting a review and authorization for cardiac imaging. Details on the outpatient cardiac imaging process will be forthcoming in a letter that should be received by early June for those providers that would request these procedures. Pharmacy Corner Aetna Better Health of Texas in order to meet NCQA standards must notify providers of all Vendor Drug Program formulary additions, deletions and changes. The following changes have been made to the VDP Preferred list and Non Preferred Drug list. Preferred Drug List Brunavil (buprenonorphine/naloxone) Cosentyx (secukinumab) Dyanavel (amphetamine) Epclusa (Velpatasvir/sofosbuvir) erythromycin base glyburide/metformin Granix (tbo gilgrastim) halobetasol metformin XR Neupogen (filgrastim) vial Quillachew ER (methylphenidate) tindazole (gastrointestinal antibiotic) Valcyte Tablets (antivirals) Viekera XR Non Preferred Drug List Adzenyz ODT (amphetamine) alogliptin alogliptin/metformin alogilptin/pioglitazone Bydureon Erythrocin Flurandrenolide Fortamat glipizide/metformin Glucophage Glucophage XR Glumetza Humalin 500 units/ml pen Jentadueto XR Luekine (sargrasmastim) metformin ER (Fortamet and Glumetza) Nanmenda XR (Alzheimer agent) neomycin/polymixin/gramicidin ophthalmic suspension Ocaliva (obeticholic acid) Bile Salts olopatadine oxiconazole Ozentra Xsail (sumatriptan) paliperidone pimozide Prednisone Dose pak repaglinide Riomet sulfacetamide ointment and suspension Sernivo (betamethasone propionate) sulfacetamide ointment and suspension Tinadamax (tindazole) gastrointestinal antibiotic Tobradex Suspension ophthalm tolnafate Triamincinolone aerosol and lotion Trintellix (vartioxetine) antidepressant Valcyte Solution valganciclovir tablets XTampza XR (analgesic non narcotic) Xrylix (diclofenac) Vraylar (cariparizine) antipsychotics Zario (filgrastim Sndz) Zembrace Symtouch (sumatriptin) Zepitier 2

3 Allergic Rhinitis Second generation antihistamines may be prescribed first line for allergic rhinitis. Along with prescribing appropriate medication, it important to counsel members and caregivers on environmental controls (Children s Hospital of Philadelphia: Intranasal steroids are useful for the management of allergic rhinitis when a second generation oral antihistamine alone is not sufficient. 1 Currently, no studies prove superiority of one intranasal corticosteroid product over another. See below the available preferred agents on the Texas Medicaid Formulary, preferred product categories are highlighted in yellow. This summary provides the available products and their Texas Medicaid Preferred Drug List status. TEXAS VENDOR DRUG PROGRAM FORMULARY 2 * ALLERGIC RHINITIS NASAL AGENTS Highlights represent preferred status in 2016 PREFERRED AGENTS NON PREFERRED AGENTS Corticosteroids Nasal NASONEX (mometasone) fluticasone (generic Flonase) BECONASE AQ (beclomethasone) FLONASE (fluticasone) FLONASE OTC (fluticasone) NASACORT OTC (triamcinolone) NASACORT AQ (triamcinolone) OMNARIS (ciclesonide) QNASL (beclomethasone dipropionate) RHINOCORT AQUA (budesonide) triamcinolone VERAMYST (fluticasone furoate)isolide) ZETONNA (ciclesonide) budesonide lunisolide Antihistamines Nasal PATANASE (olopatadine) PAZEO (olopatadine) ASTELIN (azelastine) ASTEPRO (azelastine) ATROVENT (ipratropium) nasal spray azelastine ipratropium nasal spray ipratropium nasal spray Combinations DYMISTA (azelastine/fluticasone) TEXAS VENDOR DRUG PROGRAM FORMULARY 2 * ALLERGIC RHINITIS ORAL SECOND GENERATION ANTIHISTAMINES (NON SEDATING OR MINIMALLY SEDATING) cetirizine solution, tablets loratadine ODT, solution, tablets ALLEGRA (fexofenadine) CLARINEX (desloratadine) CLARITIN (loratadine) XYZAL (levocetirizine) ZYRTEC (cetirizine) cetirizine chewable desloratadine fexofenadine levocetirizine References: 1 Wallace DV, Dykewicz MS, Bernstein DI, Blessing Moore J, Cox L, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CC, Schuller D, Spector SL, Tilles SA. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1 S84. 2 TX VDP Formulary (Last Update July 2013) 3

4 Improving Continuity of Care for Children with ADHD Attention deficit/hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders of childhood and often continues into adulthood. Children with ADHD have trouble paying attention and controlling impulsive behavior such that it often interferes with their daily lives at home, at school, at work, and in social settings. ADHD can have serious consequences on a child s development, including difficulty making friends or being accepted by his/her peers. Aetna Better Health Texas supports the recommendation and guidelines of the American Academy of Pediatrics: ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents. These ADHD guidelines are intended for use by a primary care provider working in a primary care setting to assess, diagnose, treat, and refer a patient, if needed, to a behavioral health specialist. According to the guidelines the PCP should initiate the evaluation and if the patient is thought to have ADHD he/she should prescribe medication and encourage parent and/or teacher administered behavior therapy. Both behavior therapy and medications have been demonstrated to reduce behaviors associated with ADHD and improve function. Follow up recommendations for children include 3 follow up visits over a 10 month period. The 1st appointment should occur within 30 days after the child begins medication. The next follow up appointments should occur over the next 9 months. Tips for Providers: Schedule the initial follow up appointment for 2 3 weeks and complete this task before the patient leaves the office. Educate the parent/guardian about ADHD. Encourage the parent/guardian to ask questions about ADHD. Encourage the parent/guardian to call the office if they have any concerns about the medication before the next appointment. Educate the parent/ guardian about the importance of follow up care. Encourage the parent/ guardian to consider therapy and learn how to manage ADHD behaviors in the home. No refills unless the child has the initial follow up visit. After the initial follow up visit, schedule at least 2 more visits over the next 9 months to check the child s progress. 4

5 Promoting Good Outcomes for Depression Management Prescription of antidepressant medications has been shown to be a critical part of the effective care of patients with depression. The consequences of untreated or inadequately treated depression are significant, and taking antidepressant medication correctly is a very important part of appropriate treatment. When medications are used together with appropriate forms of psychological therapy, most patients experience good outcomes. Patients need to be monitored very carefully during the first three to six months of treatment so that the clinician can adjust the dosage or type of medication, if necessary. Taking the correct medication as it is prescribed and for the prescribed amount of time is vitally important to the long term health and well being of the patient. Aetna Better Health Texas supports the recommendation and guidelines of the American Psychiatric Association s Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. When pharmacotherapy is part of the treatment plan, it must be integrated with the psychiatric management and any other treatments that are being provided. Patients who have started taking an antidepressant medication should be carefully monitored to assess their response to pharmacotherapy as well as the emergence of side effects, clinical condition and safety. Tips for Providers: Schedule follow up appointments before the patient leaves the office. Educate the patient about their diagnosis and treatment plan. Encourage the patient to ask questions about depression and ongoing care. Inform the patient that the medication may take several weeks to become effective. Inform the patient about potential side effects/ reactions and encourage them to call the office with their concerns. Inform the patient that they should not stop medication abruptly and call the office for assistance. Stress the importance of medication compliance. Encourage therapy to address life stressors and build healthy coping skills. Outreach patients that cancel appointments and have not rescheduled. Utilization Management The purpose of the utilization management department is to coordinate delivery of the best possible care to members and manage the use of health care resources to ensure an effective and efficient physical and behavioral health care delivery system. The UM department adheres to the below timelines for making coverage determinations. Within 3 business days after receipt of the request for routine authorization of services Within 1 business day after receipt of the request for urgent authorization of services Within 1 business day for concurrent hospitalization decisions Requests for urgent care services that do not qualify as urgent will be handled within the routine authorization of services timeline. Routine care or elective surgeries are examples of care that typically would not qualify as urgent. To avoid rescheduling of appointments, please keep in mind the timelines above for making coverage determination prior to the appointment being made. The following are the fax numbers to submit your requests. Please submit the Texas Standard Prior Authorization of Services form and include all pertinent information, ICD 10 code(s), dates of service and signature. STAR Kids Long Term Services and Supports (LTSS) Fax: Acute Services Prior Authorization Fax: Concurrent Review: To prevent delays in processing requests, please submit requests on the correct form and fax to the designated fax number. 5

6 AETNA BETTER HEALTH OF TEXAS Provider Relations P.O. Box Dallas, TX Who to call? Provider Relations and Member Services lines: Medicaid Bexar Medicaid Tarrant CHIP Bexar CHIP Tarrant Superior Vision LogistiCare Medical Transportation (For Medicaid members only) (Aetna Bexar County) (Aetna Tarrant County) Nurse Line Behavioral Health Provider Credentialing Report Fraud, Waste or Abuse Fax Numbers Aetna Prior Authorization fax# Aetna Inpatient Authorization fax# Behavioral Health Prior Authorization fax # (Concurrent Review) Dental MCNA Dental Denta Quest (Medicaid) (CHIP) Vital Savings (adults only) CVS Caremark (Pharmacy) CVS Caremark Help Desk BIN# PCN: ADV GROUP# RX8801 Prior Auth Call In Prior Auth fax

Oral Agents. Fml Limits. Available Strengths NF NF

Oral Agents. Fml Limits. Available Strengths NF NF MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Allergy Medications LAST REVIEW: 9/12/2017 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 9/16, 5/15, 9/14

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Ragwitek) Reference Number: CP.PMN.83 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial, Medicaid See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky (Oralair) Reference Number: CP.PMN.85 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid

More information

Oral Agents. Formulary Limits. Available Strengths. IR: 4mg ER: 12mg Syrup: 2mg/5ml

Oral Agents. Formulary Limits. Available Strengths. IR: 4mg ER: 12mg Syrup: 2mg/5ml MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 9/20/2016 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/16, 5/15,

More information

Triage Information: 1. Duration of HPSJ Membership 2. Age 3. Fill history of Seasonal Allergy Medications

Triage Information: 1. Duration of HPSJ Membership 2. Age 3. Fill history of Seasonal Allergy Medications MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Seasonal Allergy Medications LAST REVIEW: 5/28/2015 THERAPEUTIC CLASS: Rheumatologic/Immunologic REVIEW HISTORY: 5/15, 9/14

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Grastek) Reference Number: CP.PMN.84 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Antihistamines Reference Number: CP.HNMC.18 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal

Clinical Policy: Antihistamines Reference Number: CP.HNMC.18 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal Clinical Policy: Reference Number: CP.HNMC.18 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important

More information

The Medical Letter. on Drugs and Therapeutics. Drug Some Formulations OTC/Rx Usual Dosage Comments Class Comments Cost 1

The Medical Letter. on Drugs and Therapeutics. Drug Some Formulations OTC/Rx Usual Dosage Comments Class Comments Cost 1 The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

PREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit.

PREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit. PREPARATION FOR ALLERGY TESTING *** Please read this information at least one week before your upcoming visit. In order to obtain valid and useful skin testing results, you will need to stop the use of

More information

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011 Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 211 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: House dust mite allergen extract (Odactra) Reference Number: CP.PMN.111 Effective Date: 08.01.17 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important

More information

Coverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010

Coverage Criteria: Express Scripts, Inc. monograph dated 03/03/2010 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Xolair (omalizumab) Commercial HMO/PPO/CDHP HMO/PPO/CDHP: Rx

More information

Pharmacy Updates Summary

Pharmacy Updates Summary All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 01/21/2015 Effective date: 02/21/2015 Therapeutic Classes reviewed: Allergen-Specific Immunotherapy

More information

Berkshire Allergy & Asthma Center 2210 Ridgewood Road, Suite 100 Wyomissing, PA (610)

Berkshire Allergy & Asthma Center 2210 Ridgewood Road, Suite 100 Wyomissing, PA (610) Berkshire Allergy & Asthma Center 2210 Ridgewood Road, Suite 100 Wyomissing, PA 19610 (610) 372-0502 It is with pleasure that we welcome you as a new patient to Berkshire Allergy & Asthma Center, a division

More information

Health New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015.

Health New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015. April 17, 2015 FULLY FUNDED PLANS ONLY RE: Semi-Annual Notice of Changes Dear HNE Member: Health New England (HNE) is making some changes to your Plan, most of which become effective July 1, 2015. I have

More information

Jagdeep Hundal, MD, Otolaryngology, Head & Neck Surgery 774 Christiana Rd, Suite B4, Newark, DE Phone: Fax:

Jagdeep Hundal, MD, Otolaryngology, Head & Neck Surgery 774 Christiana Rd, Suite B4, Newark, DE Phone: Fax: Allergy Questionnaire Patient Name Date / / 1. What symptoms do you suffer from? Please circle below Eyes: Itchy eyes, tearing, eye redness, eye discharge Ears: Popping sensation, fullness, itching Nose/Sinus:

More information

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32

More information

OHIO MEDICAID PHARMACY COVERAGE

OHIO MEDICAID PHARMACY COVERAGE OHIO MEDICAID PHARMACY COVERAGE This information is intended for use by providers to help select the most appropriate cost-effective medication and formulation for their patients. Prescribers should utilize

More information

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma

Allergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Grastek, Oralair, Ragwitek) Reference Number: CP.CPA.111 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of

More information

Nasonex vs claritin The Borg System is 100 % Retrievable & Reusable Nasonex vs claritin

Nasonex vs claritin The Borg System is 100 % Retrievable & Reusable Nasonex vs claritin Nasonex vs claritin The Borg System is 100 % Nasonex vs claritin Claritin (loratadine) is a once-daily medicine for allergies that won't make you as sleepy as other medicines that work like it. Zyrtec

More information

Key Behavioral Health Measures (18 Years and Older)

Key Behavioral Health Measures (18 Years and Older) At WellCare, we value everything you do to deliver quality care for our members your patients to make sure they have a positive health care experience. That s why we ve created this easy-to-use, informative

More information

Next page. Name MRN DOB Date. Telephone H W M. Pharmacy

Next page. Name MRN DOB Date. Telephone H W M. Pharmacy University of Texas Medical School at Houston Department of Otorhinolaryngology- Head & Neck Surgery Texas Sinus Institute www.ut-ent.org New Patient Questionnaire Rev. 2014-07-19 FINAL REV Page 1 of 7

More information

Sinusitis. What are the sinuses? Who develops sinusitis?

Sinusitis. What are the sinuses? Who develops sinusitis? Sinusitis Health experts estimate that 37 million Americans are affected by sinusitis every year. Americans spend nearly $6 billion each year on health care costs related to sinusitis. Sinusitis is an

More information

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL* Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

More information

Provider Newsletter Fall 2018

Provider Newsletter Fall 2018 Provider Newsletter Fall 2018 Pharmacy Corner Dr. Nneka Cos-Okpalla, PharmD, MBA Texas Drug Utilization Review Board The Texas Drug Utilization Review Board held its quarterly meeting on July 27, 2018,

More information

MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS

MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS The November 22, 2016 Mid-Year Financial Report referred to changes to drug coverage under the Saskatchewan Drug Plan. What

More information

Drug Effectiveness Review Project Literature Scan Summary. Month/Year of Review: January 2015 Date of Last Review: January 2013

Drug Effectiveness Review Project Literature Scan Summary. Month/Year of Review: January 2015 Date of Last Review: January 2013 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503 947 1119 Copyright 2012 Oregon State University. All Rights

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective

More information

ALLERGIC RHINITIS-NASAL

ALLERGIC RHINITIS-NASAL ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step

More information

Volume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010

Volume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010 Volume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010 PACEF Recommendations Recommended medicines remain the same as in recent years: Non-sedating antihistamines: generic

More information

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17 Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Allergic Rhinitis: When to Refer to an Allergist

Allergic Rhinitis: When to Refer to an Allergist Allergic Rhinitis: When to Refer to an Allergist Kirsten Kloepfer, MD, MS Assistant Professor of Pediatrics Section of Pulmonary, Allergy and Sleep Medicine Disclosures NIH K23 American Academy of Allergy,

More information

Latest advances in the management of childhood allergic rhinitis

Latest advances in the management of childhood allergic rhinitis Latest advances in the management of childhood allergic rhinitis Jason Y K Chan Assistant Professor Department of Otorhinolaryngology, Head & Neck Surgery The Chinese University of Hong Kong Disclosures

More information

II. UF CLASS REVIEWS NASAL ALLERGY DRUGS

II. UF CLASS REVIEWS NASAL ALLERGY DRUGS DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code

More information

Drug Class Review Newer Antihistamines

Drug Class Review Newer Antihistamines Drug Class Review Newer Antihistamines Preliminary Scan Report 1 Update 3 November 2012 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms

More information

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018 TEST Network Health Insurance Corporation NetworkCares Step Therapy Last Updated 11/2018 ANTICONVULSANT THERAPY Aptiom Banzel Briviact Celontin Dilantin 30 Mg Capsule Equetro Fycompa 0.5 Mg/ml Oral Susp

More information

KEY BEHAVIORAL MEASURES

KEY BEHAVIORAL MEASURES 2019 HEDIS AT-A-GLANCE: KEY BEHAVIORAL MEASURES (17 Years and Younger) At WellCare, we value everything you do to deliver quality care for our members your patients to make sure they have a positive healthcare

More information

XOLAIR (omalizumab) Prior Authorization

XOLAIR (omalizumab) Prior Authorization MP9309 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below May only be prescribed by Allergy, Pulmonary, Immunology or Dermatology specialists

More information

Disclosure. OTC Review with a Pediatric Twist. Objectives. When to Call a Doctor for Infant. When to Call a Doctor for Child

Disclosure. OTC Review with a Pediatric Twist. Objectives. When to Call a Doctor for Infant. When to Call a Doctor for Child OTC Review with a Pediatric Twist Disclosure Consultant for Johnson and Johnson Baby Jill A. Morgan, PharmD, BCPS February 2015 Objectives List situations when a child should be referred to physician.

More information

Key Behavioral Measures (17 Years and Younger)

Key Behavioral Measures (17 Years and Younger) 2018 HEDIS At-A-Glance Key Behavioral Measures (17 Years and Younger) At WellCare/Harmony, we value everything you do to deliver quality care for our members your patients to make sure they have a positive

More information

Allergic Rhinitis 6/10/2016. Clinical and Economic Impact. Clinical and Economic Impact. Symptoms. Genetic/Environmental factors

Allergic Rhinitis 6/10/2016. Clinical and Economic Impact. Clinical and Economic Impact. Symptoms. Genetic/Environmental factors I have no disclosures to make other than I too suffer from allergic rhinitis Allergic Rhinitis Betsy Close, MD Assistant Professor UT College of Medicine, Department of Family Medicine Clinical and Economic

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium fluticasone furoate, 27.5 micrograms /actuation nasal (Avamys ) No. (544/09) GlaxoSmithKline 06 March 2009 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

TABLE OF CONTENTS (Click on a link below to view the section.)

TABLE OF CONTENTS (Click on a link below to view the section.) Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral

More information

2012 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members

2012 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members 2012 Chronic Respiratory Program Evaluation Our mission is to improve the health and quality of life of our members 2012 Chronic Respiratory Program Evaluation Program Title: Chronic Respiratory Program

More information

Pain Oral-Intranasal Fentanyl (Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys)

Pain Oral-Intranasal Fentanyl (Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys) Pennsylvania Employees Benefit Trust Fund (PEBTF) and n- Medicare Eligible Retired Employees Health Program (REHP), Step Therapy and Quantity Limit List Your doctor needs to get prior authorization for

More information

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018

More information

CAMPER APPLICATION PACKET

CAMPER APPLICATION PACKET CAMPER APPLICATION PACKET Monday- Friday June 12-16, 2017 Rockport, Texas DEADLINE FOR SUBMITTING ALL FORMS: THE IMPORTANCE OF COMPLETING ALL CAMP FORMS Although it may seem like a lot of paperwork, the

More information

Opinion 5 February 2014

Opinion 5 February 2014 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 5 February 2014 DYMISTA 137 µg/50 µg, nasal spray suspension Bottle with 23 g suspension of 25 ml or around 120 doses

More information

Safe, effective, affordable drug choices: online tool for payers and patients.

Safe, effective, affordable drug choices: online tool for payers and patients. Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers

More information

Hedis Behavioral Health Measures

Hedis Behavioral Health Measures Hedis Behavioral Health Measures Generating better health outcomes and improving HEDIS scores is a positive outcome for everyone. Magellan Complete Care is offering support by providing the details of

More information

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary

Formulary Changes. One mission: you TABLE A. FORMULARY CHANGES 7/1/2018: Commercial 3-Tier Formulary. Commercial 4-Tier Formulary One mission: you Changes July 1, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for

More information

KEY BEHAVIORAL MEASURES

KEY BEHAVIORAL MEASURES 2019 HEDIS AT-A-GLANCE: KEY BEHAVIORAL MEASURES (18 Years and Older) At WellCare, we value everything you do to deliver quality care for our members your patients to make sure they have a positive healthcare

More information

Drug Class Review. Newer Antihistamines

Drug Class Review. Newer Antihistamines Drug Class Review Newer Antihistamines Preliminary Scan Report #3 February 2015 Last Report: Update #2, May 2010 The purpose of reports is to make available information regarding the comparative clinical

More information

ABCBS PCMH Specifications. ARKANSAS BLUE CROSS and BLUE SHIELD An Independent Licensee of the Blue Cross and Blue Shield Association

ABCBS PCMH Specifications. ARKANSAS BLUE CROSS and BLUE SHIELD An Independent Licensee of the Blue Cross and Blue Shield Association ABCBS PCMH 2016 Specifications An Independent Licensee of the Blue Cross and Blue Shield Association Table of Contents I. Terminology 3 II. Transformation Activities 2016 List of Activities 4 3 month 5-9

More information

ALLERGY & ASTHMA ASSOCIATES PLEASE ARRIVE 15 MINUTES BEFORE YOUR APPOINTMENT TO PROCESS THE PAPERWORK - BRING ALL INSURANCE CARDS

ALLERGY & ASTHMA ASSOCIATES PLEASE ARRIVE 15 MINUTES BEFORE YOUR APPOINTMENT TO PROCESS THE PAPERWORK - BRING ALL INSURANCE CARDS ALLERGY & ASTHMA ASSOCIATES Harold Kreithen, M.D. Neil Feldman, D.O. Candace Kubek, C.R.N.P. This is to confirm your appointment on: Location: PLEASE ARRIVE 15 MINUTES BEFORE YOUR APPOINTMENT TO PROCESS

More information

SAN DIEGO ALLERGY ASTHMA & IMMUNOLOGY CONSULTANTS, INC

SAN DIEGO ALLERGY ASTHMA & IMMUNOLOGY CONSULTANTS, INC SAN DIEGO ALLERGY ASTHMA & IMMUNOLOGY CONSULTANTS, INC BERNARD A. FEIGENBAUM, M.D. FACP, FAAAAI 9850 GENESEE AVE, SUITE 355 CLINICAL ASSISTANT PROFESSOR OF MEDICINE & OTOLARYNGOLOGY, NYU LA JOLLA, CA 92037

More information

Drug Prior Authorization Guideline NUCALA (mepolizumab)

Drug Prior Authorization Guideline NUCALA (mepolizumab) Drug Prior Authorization Guideline MB9914 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Restricted to Pulmonology, Allergy, and

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE February 18, 2015 SUBJECT EFFECTIVE DATE January 21, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Drug List (PDL) Update January 21, 2015 Pharmacy Services Vincent D. Gordon, Deputy

More information

Secretary for Health and Family Services Selections for Preferred Products

Secretary for Health and Family Services Selections for Preferred Products Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based

More information

MEDICAL ASSISTANCE BULLETIN

MEDICAL ASSISTANCE BULLETIN ISSUE DATE SUBJECT EFFECTIVE DATE January 20, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See Below BY Drug List (PDL) Update January 20, 2016 Pharmacy Services Leesa M. Allen, Deputy Secretary Office of

More information

HUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012

HUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012 Behavioral Health Health and Behavior Assessments (CPT 96150-96155) When Performed by Psychologists Mental Health Inpatient 100% covered under medical benefit for members with diagnoses outside the range

More information

BYSTOLIC. Products Affected Step 2: BYSTOLIC 10 MG TABLET BYSTOLIC 2.5 MG TABLET. Details BYSTOLIC 20 MG TABLET BYSTOLIC 5 MG TABLET

BYSTOLIC. Products Affected Step 2: BYSTOLIC 10 MG TABLET BYSTOLIC 2.5 MG TABLET. Details BYSTOLIC 20 MG TABLET BYSTOLIC 5 MG TABLET BYSTOLIC BYSTOLIC 10 MG TABLET BYSTOLIC 2.5 MG TABLET BYSTOLIC 20 MG TABLET BYSTOLIC 5 MG TABLET authorization for a Step 2 drug may be given. Step 1 Drug(s): generic beta-blockers and/or combinations,

More information

Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants

Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants AETNA BETTER HEALTH Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants Formulary amphetamine/dextroamphetamine IR, ER (generic

More information

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists

Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior

More information

ESTABLISHED PATIENT INFORMATION

ESTABLISHED PATIENT INFORMATION Leaders in outcomes oriented, evidence based, compassionate, cost effective care ESTABLISHED PATIENT INFORMATION Hello, We are delighted that you have scheduled an appointment with Pulmonary Medicine,

More information

**No food or beverages are allowed in the exam room**

**No food or beverages are allowed in the exam room** ALLERGY & ASTHMA ASSOCIATES Neil Feldman, D.O. Rebecca Aul, C.R.N.P. This is to confirm your appointment on: Location: PLEASE ARRIVE 15 MINUTES BEFORE YOUR APPOINTMENT TO PROCESS THE PAPERWORK - BRING

More information

Step Therapy Criteria 2019

Step Therapy Criteria 2019 Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD

More information

Treatment of Allergic Rhinitis

Treatment of Allergic Rhinitis Treatment of Allergic Rhinitis DENISE K.C. SUR, MD, and MONICA L. PLESA, MD, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California Allergic rhinitis is a common

More information

A new code for this year! G9153

A new code for this year! G9153 SM www.bluechoicescmedicaid.com Volume 5, Issue 1 February 2017 2017 Incentive Payments: A new code for this year! G9153 The South Carolina Department of Health and Human Services (SCDHHS) has identified

More information

TABLE OF CONTENTS (Click on a link below to view the section.)

TABLE OF CONTENTS (Click on a link below to view the section.) Follow the links below to access the complete formularies for Plans: Buckeye Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral

More information

Generics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m

Generics. Lead with. P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m Lead with Generics P r e s c r i p t i o n S t e p T h e r a p y P r o g r a m WWW.BCBSLA.COM 04HQ3972 5/09 Blue Cross and Blue Shield of Louisiana incorporated as Louisiana Health Service & Indemnity

More information

ODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet

ODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet pteronyssinus) allergen extract sublingual tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.

More information

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication. ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE

More information

ARIA. At-A-Glance Pocket Reference 2007

ARIA. At-A-Glance Pocket Reference 2007 ARIA_Glance_2007_8pg:ARIA_Glance_English 9/14/07 3:10 PM Page 1 ARIA At-A-Glance Pocket Reference 2007 1 st Edition NEW ARIA UPDATE BASED ON THE ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA WORKSHOP REPORT

More information

ADMINISTRATION OF MEDICATIONS AT THE WALDORF SCHOOL OF PRINCETON

ADMINISTRATION OF MEDICATIONS AT THE WALDORF SCHOOL OF PRINCETON ADMINISTRATION OF MEDICATIONS AT THE WALDORF SCHOOL OF PRINCETON MEDICATION DURING SCHOOL HOURS Whenever possible, the parent/guardian should arrange with their physician for medication to be given outside

More information

ANTICONVULSANT THERAPY

ANTICONVULSANT THERAPY Network Health Insurance Corporation NetworkCares Step Therapy Last Updated: 7/2017 ANTICONVULSANT THERAPY Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200

More information

Allergic rhinitis (AR) is a highly prevalent disease, affecting

Allergic rhinitis (AR) is a highly prevalent disease, affecting Cost Efficiency of Intranasal Corticosteroid Prescribing Patterns in the Management of Allergic Rhinitis DEBI REISSMAN, PharmD; TOM PRICE, BA; and CHRISTOPHER W. LEIBMAN, PharmD, MS ABSTRACT BACKGROUND:

More information

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date:

Clinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Brown-Lupton Health Service Texas Christian University Campus P.O. Box Fort Worth, TX Dear Student,

Brown-Lupton Health Service Texas Christian University Campus P.O. Box Fort Worth, TX Dear Student, Brown-Lupton Health Service Texas Christian University Campus P.O. Box 297400 Fort Worth, TX 76129 817-257-7940 Dear Student, Enclosed you will find our policies, procedures and student consent form for

More information

Allergic Rhinitis Diagnosis. Allergic Rhinitis Economic Burden. Allergic Rhinitis Epidemiology. Allergic Rhinitis Quality of Life

Allergic Rhinitis Diagnosis. Allergic Rhinitis Economic Burden. Allergic Rhinitis Epidemiology. Allergic Rhinitis Quality of Life Allergic Rhinitis Epidemiology 6th Leading cause of chronic illness > 50m Americans suffer from allergies 10-30% Children and adults affected in U.S. 2.5% Of all clinician visits 1. US Department of Health

More information

3. Does the member continue to receive nutritional or psychological counseling?

3. Does the member continue to receive nutritional or psychological counseling? Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS CS Stimulants (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Pharmacy Updates Summary

Pharmacy Updates Summary All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines

More information

Cerebral Stimulant and ADHD Drugs Prior Authorization Request

Cerebral Stimulant and ADHD Drugs Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization

More information

2015 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members

2015 Chronic Respiratory. Program Evaluation. Our mission is to improve the health and quality of life of our members 2015 Chronic Respiratory Program Evaluation Our mission is to improve the health and quality of life of our members 2015 Chronic Respiratory Program Evaluation Program Title: Chronic Respiratory Program

More information

AETNA BETTER HEALTH OF ILLINOIS Provider Newsletter August 2016, Vol. 5

AETNA BETTER HEALTH OF ILLINOIS Provider Newsletter August 2016, Vol. 5 AETNA BETTER HEALTH OF ILLINOIS Provider Newsletter August 2016, Vol. 5 www.aetnabetterhealth.com/illinois With questions or concerns, please contact Provider Services at 866-212-2851 Option 2 Diabetes

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

Drug List exclusions for Blue Cross commercial plans

Drug List exclusions for Blue Cross commercial plans Drug List exclusions for Blue Cross commercial plans The drugs shown below aren t covered on the commercial Blue Cross Blue Shield of Michigan drug lists. In most cases, if you fill a prescription for

More information

HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE

HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE What is HEDIS? 3 HEDIS Reference Guide for Behavioral Health 4 Behavioral Health HEDIS Measures 13 WHAT IS HEDIS? HEDIS (Healthcare Effectiveness Data and Information

More information

Comments. Oral Antihistamines. Chronic Drug Treatments. Oral Allergy Medications

Comments. Oral Antihistamines. Chronic Drug Treatments. Oral Allergy Medications Comments: Even though OTC vasoconstrictors and antihistamines are popular, a recent article suggests that these drugs can cause rebound dilation of conjunctival vessels Chronic Drug Treatments Mast Cell

More information

CERTIFIED ALLERGY & ASTHMA CONSULTANTS. Patient Handbook

CERTIFIED ALLERGY & ASTHMA CONSULTANTS. Patient Handbook CERTIFIED ALLERGY & ASTHMA CONSULTANTS Patient Handbook PATIENT HANDBOOK TABLE OF CONTENTS WELCOME TO OUR PRACTICE 3 WHAT IS AN ALLERGY?... 4 WHO DEVELOPS ALLERGIES?... 4 HOW ARE ALLERGIES TREATED?...

More information

Objec9ves. Drug Classes with Indications to Treat AR. Allergic Rhinitis. Allergic Rhinitis. Action Statements

Objec9ves. Drug Classes with Indications to Treat AR. Allergic Rhinitis. Allergic Rhinitis. Action Statements Sneezes, Wheezes, and espiratory Diseases: An update on Asthma, Allergic hini5s, and COPD Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates Objec9ves Evalua9on of the latest allergic

More information

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE: DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

central oregon EAR NOSE THROAT

central oregon EAR NOSE THROAT Northwest Sinus Center Director: Ryan P. Gallivan, MD central oregon EAR NOSE THROAT New Patient Questionnaire Name MRN DOB Date Telephone H W M Pharmacy Name Telephone How did you hear about us? q Sent

More information

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications

Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

Volume 7; Number 12 July 2013

Volume 7; Number 12 July 2013 Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire

More information